What is AbbVie's new schizophrenia drug? A Look at Emraclidine and the Current Landscape
•
4 min read
An estimated 24 million people worldwide live with schizophrenia, yet medication adherence remains a challenge, with a discontinuation rate of 74% within 18 months [1.6.2]. This reality drives the search for better treatments. When asking, **What is AbbVie's new schizophrenia drug?**, the answer involves a promising but ultimately unsuccessful investigational drug named emraclidine and the company's existing portfolio.
